Jazz Pharmaceuticals (NASDAQ:JAZZ) Sees Strong Trading Volume Following Analyst Upgrade

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) saw strong trading volume on Thursday after Truist Financial raised their price target on the stock from $264.00 to $281.00. Truist Financial currently has a buy rating on the stock. Approximately 1,087,428 shares traded hands during trading, an increase of 15% from the previous session’s volume of 941,950 shares.The stock last traded at $247.8670 and had previously closed at $249.29.

A number of other research analysts also recently issued reports on JAZZ. Morgan Stanley lifted their price objective on shares of Jazz Pharmaceuticals from $283.00 to $322.00 and gave the stock an “overweight” rating in a research report on Wednesday. Bank of America raised their price objective on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. Piper Sandler increased their price target on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Raymond James Financial restated an “outperform” rating and set a $239.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 6th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Jazz Pharmaceuticals in a research report on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $279.00.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 1,200 shares of the stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total value of $278,196.00. Following the transaction, the executive vice president directly owned 51,549 shares of the company’s stock, valued at $11,950,604.67. This trade represents a 2.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $252.98, for a total value of $1,517,880.00. Following the sale, the director owned 360,682 shares in the company, valued at $91,245,332.36. This trade represents a 1.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 14,357 shares of company stock valued at $3,505,642. 4.10% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: The FDA approved two Ziihera-based regimens for first-line treatment of advanced HER2-positive gastroesophageal adenocarcinoma. The broader label covers eligible patients with different HER2 levels and, in one regimen, regardless of PD-L1 status, expanding Ziihera’s addressable market and supporting expectations for significant commercial growth. FDA approves Ziihera regimens
• Positive Sentiment: Analysts raised their targets while maintaining Buy ratings: Needham increased its target from $292 to $310, and Truist lifted its target from $264 to $281. The revisions reflect optimism surrounding Ziihera’s new indication and Jazz’s growth prospects. Analyst price target increases
• Neutral Sentiment: Jazz priced $1.1 billion of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion offering. Proceeds are being paired with concurrent ordinary-share repurchases, which could support per-share results but also increase leverage and create potential future dilution. Jazz prices exchangeable notes
• Negative Sentiment: Zacks Research reduced several forward EPS estimates, including FY2026 from $21.72 to $20.77 and FY2027 from $22.26 to $20.02. Estimates for Q3 and Q4 2026 and multiple 2027 quarters were also lowered, suggesting some pressure on near- to medium-term earnings expectations. A small increase in the Q2 2028 forecast to $6.09 provides only a partial offset.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. USA Financial Formulas acquired a new position in Jazz Pharmaceuticals during the first quarter worth $25,000. LRI Investments LLC acquired a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth $38,000. Danske Bank A S purchased a new position in shares of Jazz Pharmaceuticals in the 3rd quarter valued at about $40,000. Ameritas Advisory Services LLC purchased a new position in shares of Jazz Pharmaceuticals in the 2nd quarter valued at about $47,000. Finally, Geneos Wealth Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 57.6% in the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Trading Down 0.6%

The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. The business’s fifty day moving average is $246.38 and its 200 day moving average is $217.52. The stock has a market cap of $16.08 billion, a PE ratio of 17.10, a P/E/G ratio of 0.23 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The firm had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.11 billion. During the same quarter in the prior year, the business earned ($8.25) EPS. The company’s quarterly revenue was up 15.5% compared to the same quarter last year. As a group, analysts predict that Jazz Pharmaceuticals PLC will post 21.66 earnings per share for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.